Insulin analogues in children and teens with type 1 diabetes: advantages and caveats.
This article reviews the advantages to and caveats of the use of newer insulin formulations (insulin analogues) and regimens in children and teens who have type 1 diabetes, their affect on glycemic control, frequency of hypoglycemic events, daily insulin requirements, and adverse affects such as excessive weight gain, which provides a further major challenge in adolescents. We also address briefly the use of adjunctive agents in the treatment of type 1 diabetes in children and teens.
Rachmiel
Marianna
M
Division of Endocrinology, Department of Pediatrics, The Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.
Perlman
Kusiel
K
Daneman
Denis
D
D000293:Adolescent; D000682:Amyloid / Q000627:therapeutic use; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000032:analysis / Q000627:therapeutic use*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D058228:Islet Amyloid Polypeptide; D008687:Metformin / Q000627:therapeutic use
D000682:Amyloid; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D058228:Islet Amyloid Polypeptide; D000069036:Insulin Glargine; D052216:Glucagon-Like Peptide 1; D008687:Metformin; C105254:pramlintide